Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.
Gastrointestinal stromal tumor
Imatinib
Local treatment
Treatment interruption
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
23
12
2022
accepted:
21
02
2023
medline:
23
6
2023
pubmed:
9
3
2023
entrez:
8
3
2023
Statut:
ppublish
Résumé
Current guidelines recommend indefinite imatinib treatment for advanced gastrointestinal stromal tumor (GIST) patients. Imatinib-refractory progression-free survival (PFS) and overall survival were previously reported not to differ between GIST patients who interrupted imatinib and those who did not. Clinical outcomes of 77 consecutive patients with recurrent or metastatic GIST who interrupted imatinib treatment after maintaining years of imatinib treatment in the absence of gross tumor lesions were retrospectively analyzed. Associations between clinical factors and progression-free survival (PFS) following imatinib interruption were analyzed. The median time from the absence of gross tumor lesions to imatinib interruption was 61.5 months. Since imatinib interruption, the median PFS was 19.6 months, and 4 patients (26.3%) remained progression-free for longer than 5 years. Among the patients who had progressive disease following the interruption, imatinib re-introduction led to an 88.6% objective response rate and a 100% disease control rate. Complete removal of the initial gross tumor lesion(s) and complete removal of the residual gross tumor lesion(s) by local treatment (vs. no local treatment or residual lesions after local treatment) were independently associated with favorable PFS. Interruption of imatinib following prolonged maintenance in the absence of gross tumor lesions led to disease progression in the majority of cases. However, re-introduction of imatinib resulted in effective tumor control. Unmaintained remission seems to be possible in some patients with metastatic or recurrent GIST after a prolonged remission with imatinib if there is complete removal of any gross tumor lesions.
Sections du résumé
BACKGROUND
Current guidelines recommend indefinite imatinib treatment for advanced gastrointestinal stromal tumor (GIST) patients. Imatinib-refractory progression-free survival (PFS) and overall survival were previously reported not to differ between GIST patients who interrupted imatinib and those who did not.
METHODS
Clinical outcomes of 77 consecutive patients with recurrent or metastatic GIST who interrupted imatinib treatment after maintaining years of imatinib treatment in the absence of gross tumor lesions were retrospectively analyzed. Associations between clinical factors and progression-free survival (PFS) following imatinib interruption were analyzed.
RESULTS
The median time from the absence of gross tumor lesions to imatinib interruption was 61.5 months. Since imatinib interruption, the median PFS was 19.6 months, and 4 patients (26.3%) remained progression-free for longer than 5 years. Among the patients who had progressive disease following the interruption, imatinib re-introduction led to an 88.6% objective response rate and a 100% disease control rate. Complete removal of the initial gross tumor lesion(s) and complete removal of the residual gross tumor lesion(s) by local treatment (vs. no local treatment or residual lesions after local treatment) were independently associated with favorable PFS.
CONCLUSION
Interruption of imatinib following prolonged maintenance in the absence of gross tumor lesions led to disease progression in the majority of cases. However, re-introduction of imatinib resulted in effective tumor control. Unmaintained remission seems to be possible in some patients with metastatic or recurrent GIST after a prolonged remission with imatinib if there is complete removal of any gross tumor lesions.
Identifiants
pubmed: 36884149
doi: 10.1007/s10120-023-01377-2
pii: 10.1007/s10120-023-01377-2
doi:
Substances chimiques
Imatinib Mesylate
8A1O1M485B
Piperazines
0
Pyrimidines
0
Benzamides
0
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
604-613Informations de copyright
© 2023. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
Références
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80. https://doi.org/10.1056/NEJMoa020461 .
doi: 10.1056/NEJMoa020461
pubmed: 12181401
Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5. https://doi.org/10.1200/jco.2007.13.4403 .
doi: 10.1200/jco.2007.13.4403
pubmed: 18235121
Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32. https://doi.org/10.1200/jco.2007.13.4452 .
doi: 10.1200/jco.2007.13.4452
pubmed: 18235122
Casali PG, Zalcberg J, Le Cesne A, et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the european organisation for research and treatment of cancer, Italian sarcoma group, and australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels. J Clin Oncol. 2017;35:1713–20. https://doi.org/10.1200/jco.2016.71.0228 .
doi: 10.1200/jco.2016.71.0228
pubmed: 28362562
Kim JH, Ryu MH, Yoo C, et al. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. Cancer Med. 2019;8:1034–43. https://doi.org/10.1002/cam4.1994 .
doi: 10.1002/cam4.1994
pubmed: 30693663
pmcid: 6434201
Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:20–33. https://doi.org/10.1016/j.annonc.2021.09.005 .
doi: 10.1016/j.annonc.2021.09.005
pubmed: 34560242
Koo DH, Ryu MH, Kim KM, et al. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer Res Treat. 2016;48:1155–66. https://doi.org/10.4143/crt.2016.187 .
doi: 10.4143/crt.2016.187
pubmed: 27384163
pmcid: 5080813
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
pubmed: 33538338
Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–13. https://doi.org/10.1200/jco.2006.09.0183 .
doi: 10.1200/jco.2006.09.0183
pubmed: 17369574
Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11:942–9. https://doi.org/10.1016/s1470-2045(10)70222-9 .
doi: 10.1016/s1470-2045(10)70222-9
pubmed: 20864406
Ray-Coquard I, Bin Bui N, Adenis A, et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study. J Clin Oncol. 2010;28:10032.
doi: 10.1200/jco.2010.28.15_suppl.10032
Lee JL, Ryu MH, Chang HM, et al. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. Jpn J Clin Oncol. 2006;36:704–11. https://doi.org/10.1093/jjco/hyl088 .
doi: 10.1093/jjco/hyl088
pubmed: 17068083
Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60. https://doi.org/10.1182/blood-2006-03-011239 .
doi: 10.1182/blood-2006-03-011239
pubmed: 16973963
Kurokawa Y, Yang HK, Cho H, et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer. 2017;117:25–32. https://doi.org/10.1038/bjc.2017.144 .
doi: 10.1038/bjc.2017.144
pubmed: 28535156
pmcid: 5520207
Park SJ, Ryu MH, Ryoo BY, et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann Surg Oncol. 2014;21:4211–7. https://doi.org/10.1245/s10434-014-3866-4 .
doi: 10.1245/s10434-014-3866-4
pubmed: 24980089
Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302. https://doi.org/10.1016/s0140-6736(12)61857-1 .
doi: 10.1016/s0140-6736(12)61857-1
pubmed: 23177515
Bang YH, Ryu MH, Kim HD, et al. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib. Int J Cancer. 2022;151:1770–7. https://doi.org/10.1002/ijc.34157 .
doi: 10.1002/ijc.34157
pubmed: 35678337
Patrikidou A, Chabaud S, Ray-Coquard I, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol. 2013;24:1087–93. https://doi.org/10.1093/annonc/mds587 .
doi: 10.1093/annonc/mds587
pubmed: 23175622
Hompland I, Boye K, Papakonstantinou A, et al. Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: a prospective multicenter phase II study. J Clin Oncol. 2022; 40(16_suppl). https://doi.org/10.1200/JCO.2022.40.16_suppl.11535 .
Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014;40:412–9. https://doi.org/10.1016/j.ejso.2013.12.020 .
doi: 10.1016/j.ejso.2013.12.020
pubmed: 24491288
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Seminars in diagnostic pathology. Amsterdam: Elsevier; 2006. p. 70–83.
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.
doi: 10.1016/j.humpath.2008.06.025
pubmed: 18774375
Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261–72. https://doi.org/10.1056/NEJMoa2200075 .
doi: 10.1056/NEJMoa2200075
pubmed: 35657320
pmcid: 9701133
Bauer S, Heinrich MC, George S, et al. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021;27:6333–42. https://doi.org/10.1158/1078-0432.Ccr-21-1864 .
doi: 10.1158/1078-0432.Ccr-21-1864
pubmed: 34503977
pmcid: 9401492
Bialick S, Rose BE, Espejo-Freire AP, et al. KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor. J Clin Oncol. 2022;40(16_suppl):11514. https://doi.org/10.1200/JCO.2022.40.16_suppl.11514 .
doi: 10.1200/JCO.2022.40.16_suppl.11514
Serrano C, Bauer S, Gómez-Peregrina D, et al. Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST). J Clin Oncol. 2022;40(16_suppl):101: https://doi.org/10.1200/JCO.2022.40.16_suppl.101 .
doi: 10.1200/JCO.2022.40.16_suppl.11514
Vanden Bempt I, Vander Borght S, Sciot R, et al. Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor. Genes Chromosomes Cancer. 2021;60:239–49. https://doi.org/10.1002/gcc.22923 .
doi: 10.1002/gcc.22923
pubmed: 33258138
Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35. https://doi.org/10.1016/s1470-2045(10)70233-3 .
doi: 10.1016/s1470-2045(10)70233-3
pubmed: 20965785
Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305. https://doi.org/10.1200/jco.2016.68.2914 .
doi: 10.1200/jco.2016.68.2914
pubmed: 28095277